Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698864 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
A Phase 2 study, sponsored by Processa Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03698864 is a Phase 2 study that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT03698864, a Phase 2 study, has completed, sponsored by Processa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open-label study that will evaluate the safety of PCS499 for the treatment of necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 12 NL patients (6-9 patients without ulceration and 3-6 patients with ulceration) who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the safety and tolerability profile of PCS499 in patients with Necrobiosis Lipoidica.
Interventions
- DRUG PCS499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03698864
The ClinicalTrials.gov registry entry for NCT03698864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCS499 is the first listed.
NCT03698864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03698864 about?
NCT03698864 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica". This is an open-label study that will evaluate the safety of PCS499 for the treatment of necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 12 NL patients (6-9 patients without ulceration and 3-6 patients with ulceration) who also meet other inclusion/exclusion cr...
What is the current status of trial NCT03698864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-11-07. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT03698864?
The interventions under investigation include: PCS499 (DRUG).
Who is sponsoring clinical trial NCT03698864?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.